Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciCurrent and Future Considerations for the Treatment of Hospital-Acquired PneumoniaUpdate on the emerging role of telavancin in hospital-acquired infectionsSafety profiles of old and new antimicrobials for the treatment of MRSA infections.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensEfficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.Antibiotics and bacterial resistance in the 21st century.Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyTelavancin: a new lipoglycopeptide with multiple mechanisms of action.Role of telavancin in treatment of skin and skin structure infectionsTelavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin (vibativ), a new option for the treatment of gram-positive infectionsCurrent and novel antibiotics against resistant Gram-positive bacteriaTelavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infectionsPharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.Population pharmacokinetics of telavancin in healthy subjects and patients with infections.Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureusTelavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).New advances in antibiotic development and discovery.Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.Case report: artificial elevation of prothrombin time by telavancinTreatment options for multidrug-resistant bacteria.Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts).Investigational treatments for postoperative surgical site infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Telavancin: a novel lipoglycopeptide for serious gram-positive infections.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Vancomycin resistance: are there better glycopeptides coming?Telavancin: a novel lipoglycopeptide antibiotic.Transplacental transfer of vancomycin and telavancin
P2860
Q26827380-29CFE133-395F-47C3-ABEC-64AFEE0504D9Q26853465-0FF23BB9-0683-4ED2-90A2-7E066C8E9285Q28071882-821EB6E7-5EC3-4D96-A565-40B21472842FQ28083522-79F29D17-A6D9-4B84-A027-2F6353E5366BQ33429168-26FF028B-9BF3-41FC-B2FE-B4C36E2EE9A5Q33657212-9D070D70-0F18-4833-8A3B-11C12959DC34Q33788308-91ACCEDC-3B9A-44FE-B923-33CDCA3BE2B6Q34077052-8C706B71-5D10-4A38-9F99-45ED496407DCQ34156349-12ECDC03-C33F-469B-BC38-D3DDDC5F6046Q34509652-2D32A6F7-F5A3-42F1-8534-C6AEBABB9456Q34572923-536B257C-E770-4D35-A8B8-4397540AF6E5Q34620329-1111B094-AFEC-4EA0-95F1-90E4D66C195CQ34677611-612B3C46-06D7-4118-8D0B-AE087EDE6660Q34906520-C0ADA620-F1CA-4C11-A895-7F45C47CEFC4Q35026521-36227AE8-0101-4047-9199-0EC99152839BQ35026607-519019EA-D8E6-4247-BF06-3A82F3234255Q35603288-36AA859E-0347-4697-9694-8E386CAC2B2AQ35678198-805BD3C2-1069-44F7-ADE1-3362FC04970AQ35867360-442C07C2-D8A8-4895-AB95-269DBE63E5D0Q35867522-0EEF667D-B290-4A64-BE3E-6BB4072969B4Q35879100-ECC037F4-AAC6-46B2-A60C-B2B481E8B8DAQ35905561-22FA572C-EAE7-4F8A-9084-4D684A64B016Q36065983-F723D4BD-0024-44DF-9506-34531D282069Q36422696-CEFBE569-165D-4F39-B404-B2BB2DD63E9AQ36439168-AE466917-EDB5-4292-9C95-35E40A569824Q36484733-3D085E29-443C-465C-B306-37BCAC0B0908Q36607401-1ABFD209-E41C-4BEE-8D7C-66FDD9264CD0Q36660619-B7096714-59D2-4520-A973-1B7587BDE06DQ36715742-83720279-1BD1-4939-9B99-696A56897378Q36718474-F5C0C014-CB99-4390-B394-0644A0D60CB7Q36736356-D0014429-06C4-4BEC-8821-E06C68B95A81Q36968150-0D13DDA2-F62E-4D72-982A-99BE5C5E0694Q37071199-398A8D0B-CFC4-42CE-845E-74FD4DB55A2DQ37077627-B88716BB-245F-4C2B-A53D-1C238C5B2657Q37077629-C27FC823-CB85-4F20-8188-699168C1026CQ37117865-8E6BA01A-138F-4861-BA33-457D23826B2EQ37252733-911C54AB-B022-489F-8C21-E4E939129AA0Q37340562-939365E6-AB8F-459D-8FF1-E9289DAE4D6EQ37463589-75FE128A-7A6B-41DB-9F9C-39C3C997F0E2Q37478888-37A68E9C-24BE-4735-BD3C-37DF03960A1B
P2860
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@ast
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@en
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@nl
type
label
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@ast
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@en
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@nl
prefLabel
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@ast
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@en
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@nl
P2093
P2860
P1476
Pharmacokinetics, serum inhibi ...... elavancin in healthy subjects.
@en
P2093
P2860
P304
P356
10.1128/AAC.49.1.195-201.2005
P407
P577
2005-01-01T00:00:00Z